There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verona Pharma (VRNA – Research Report), Trevi Therapeutics (TRVI – Research Report) and Cooper Co (COO – Research Report) with bullish sentiments.
Verona Pharma (VRNA)
Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Verona Pharma today and set a price target of $31.00. The company’s shares closed last Wednesday at $21.16.
According to TipRanks.com, Rahimi is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Verona Pharma with a $32.50 average price target, a 51.9% upside from current levels. In a report issued on May 9, BTIG also assigned a Buy rating to the stock with a $31.00 price target.
See the top stocks recommended by analysts >>
Trevi Therapeutics (TRVI)
In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics, with a price target of $6.00. The company’s shares closed last Wednesday at $2.47.
According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Trevi Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.80, implying a 173.1% upside from current levels. In a report issued on May 12, Needham also reiterated a Buy rating on the stock with a $8.00 price target.
Cooper Co (COO)
In a report released today, Jason Bednar from Piper Sandler maintained a Buy rating on Cooper Co, with a price target of $430.00. The company’s shares closed last Wednesday at $376.54, close to its 52-week high of $395.20.
According to TipRanks.com, Bednar ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Cooper Co is a Strong Buy with an average price target of $408.57, implying a 7.9% upside from current levels. In a report issued on May 15, Wells Fargo also maintained a Buy rating on the stock with a $430.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VRNA:
- Verona Pharma to Present at Jefferies Healthcare Conference
- Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
- VRNA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
- Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
